In a report published Friday, Stifel analyst Robert Mains reiterated a Buy rating on HCP HCP, but lowered the price target from $53.00 to $51.00.
In the report, Stifel noted, “We are making modest adjustments to our HCP model to reflect 2013 and 2014 debt maturities and Tenet Healthcare's (THC: $40.68 - Not Covered) purchase option exercises on three hospitals. As a result, we are also slightly lowering 2014 financing assumptions and general and administrative expense. There is no net impact to our FFO and FAD estimates, which remain $3.00 and $2.50 per share, respectively, in 2013 and $3.10 and $2.62 per share, respectively, in 2014. As our target price is based partly on relative valuations, we are lowering it from $53 to $51, as the FAD multiple for S&P 500 REITs has declined.”
HCP closed on Thursday at $39.71.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
---|
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in